Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIORELLA: Tailored Treatment in Elderly PCNSL
NCT03495960Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in primary central nervous system lymphoma (PCNSL) (3 arms), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Progression-Free Survival (Part A) at 2 years and Progression-Free Survival (Part B) at 2 years. Started Jun 2019; status: completed.
02
Drugs
lenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03495960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495960.